Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.

Abstract excerpt

Although the Jak2-V617F mutation has generated strong awareness because of its causative role in myeloproliferative disorders, reports of Jak2 gene aberrations linked to hematologic malignancies have preceded those of V617F by nearly a decade. These malignant mutations include Jak2 amino acid substitutions, deletions, insertions, and chromosomal translocations. As a consequence, researchers are increasingly...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hematologic Neoplasms
• Share to Janus Kinase 2
• Share to Mutation